Uprima® Clinical Trials

(N = 3,035)

• Phase III
  • Three controlled crossover
  • Dose-optimization
    • One controlled parallel
    • Five long-term, open-label
    • One first dose administered at home

• Phase I

  • Pharmacokinetics
  • Metabolic fate
  • Elderly (³65 years)
  • Renal/Hepatic Impaired
  • Drug interactions (Zofran®, Compazine®)

• Special Phase I/II/III

  • Antihypertensives and nitrates
  • Diabetics
  • Alcohol
  • Prostatectomy
  • Spinal cord injury

Introduction/Uprima

Previous slide

Back to first slide

View graphic version